In order to examine the role of KRAS activation in promoting tumor tolerance in the context of p53 loss, we used previously described doxycycline (Dox)-inducible KRASG12D-driven p53-null PDAC mouse cells (Ying et al., 2012) (Figure 6A). This evidence concerns the gene KRAS and neoplasm.